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doi:10.1016/j.ejvs.2011.01.009Abstract Introduction: Is it possible by pharmacological methods to attenuate the expansion
rate of abdominal aortic aneurysms?
Method: An Internet-based systematic literature search was performed to identify published
reports on pharmacological methods to influence aneurysmal expansion rate.
Results: Of an original 450 articles, 21 remained to review: they included 15 cohort studies
with 12,321 patients and seven randomised clinical trials (RCTs) with 1069 patients. Most
studies are performed without a pre-study sample size calculation. There is no consistent
pattern of pharmacological influence on expansion rate, but statins, non-steroidal anti-inflam-
matory drugs (NSAIDs) and macrolides should be further evaluated.
Conclusion: Properly designed RCTs are needed before conclusions can be drawn on the possi-
bility to pharmacologically attenuate aneurysmal expansion and prevent rupture.
ª 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Screening and early detection with elective surgical inter-
vention is aneffectiveway todecreasemortality inabdominal
aortic aneurysmal disease, where rupture is the great threat
to a patient’s life.1 Whether open or endovascular treatment
is chosen, the interventional procedure is not without
complications, also serious ones including mortality. Knowingeducation questions on this
ation.com and click on ‘CME’
611 4632.
urgsci.uu.se.
ty for Vascular Surgery. Publishethe pathophysiology of expansion, at least theoretically, it
should be possible by pharmacological means to inhibit
expansion or decrease the rate (Cooper et al., 2009, Baxter
et al., 2008),2,3 and in several animal models this has been
possible. Theaimof this article is to systematically review the
literature on pharmacological interventions to attenuate
abdominal aortic aneurysm (AAA) expansion in humans.
Pathophysiological Background
In Fig. 1 are summarised the various aetiological and
pathophysiological factors, which have been discussed ind by Elsevier Ltd. All rights reserved.
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known, it is important to separate two processes, which
could be and most probably are different, and therefore
also need different methods to influence them: the primary
development of an AAA and the expansion when it has once
been established. Although interesting and important, this
article will not further deal with the development of an AAA,
whichwill include primary prevention.When there is an AAA,
the question is if anything can be done to inhibit or slowdown
its expansion rate and risk of rupture. The problem has
become increasingly important today, when an increasing
number of small AAAs are identified through various
screening programmes and where the diameter of less than
5 cm will not indicate invasive treatment. Expansion rate is
important to help in deciding when to intervene. The rate is
significantly reduced in non-smokers compared with smok-
ers.4e8 Diabetes mellitus may have a protective role.9 The
remaining part of this article will analyse different pharma-
cologic methods. One initial caveat is the complexity of
aneurysmal expansion with a number of genetic as well as
environmental factors of importance, thereby making
studies methodologically difficult.
Results from Animal Models
There are several animal models for development of
aneurysm. Potentially, they can be used to test substances
of interest in the clinical setting, and in fact there are
several, which have shown to be effective in attenuating
experimental aneurysmal expansion. The problem,
however, is that the animal models used do not necessarily
reflect the complex situation of aneurysmal development inAbdominal aortic aneurysm
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Figure 1 Etiological and pathogenetic factors in the devel-
opment of AAA.humans, and therefore every substance of interest has to
be evaluated in the clinical setting of patients with a small
AAA. There are at least three important characteristics in
clinical AAA, which are different from the animal models
and which probably are of importance when studying the
disease: it is a disease of the ageing individual, it coincides
with atherosclerotic alterations in the aneurysmal wall and
the aneurysmal sac usually contains thrombotic material.
Moreover, most animal models use rather artificial means to
induce aneurysmal development.
Method
A systematic literature search has been made in EMBASE,
Cochrane and PubMed. Both randomised controlled trials
(RCTs) and cohort studies have been accepted in dealing
with human AAA, aneurysmal expansion (growth) and
pharmacotherapy. In the identified studies, the reference
lists were scrutinised for further studies of potential
interest.
Results
A total of 460 articles on AAA and expansion were identi-
fied, 62 dealing with various aspects of pharmacotherapy.
Twenty-one studies remained for review: 15 cohort studies
with 12,321 patients (Table 1) and six RCTs with 1069
patients (Table 2). In Table 3, the results are summarised,
the remaining substances of interest being statins and
macrolides and possibly non-steroidal anti-inflammatory
drugs (NSAIDs).
In one study, primarily focussed on compliance and
safety with prolonged doxycycline and secondarily on
matrix metalloproteinase (MMP) levels, there was no
change in aneurysmal diameter over a 6 months’ period.10
There is one large non-randomised population-based
case-control study, which is of interest.11 This is a study
from a Canadian administrative database of 15,326 patients
with the aim to analyse the influence of angiotensin-con-
verting enzyme (ACE) inhibitors on the risk of AAA rupture,
which can be seen as the final outcome of aneurysmal
expansion. A total of 3379 patients were on ACE inhibitors
with an odds ratio for rupture being 0.82 (95% confidence
interval (CI) 0.74e0.90; p < 0.0001). In another observa-
tional study, also from Canada, renin-angiotensin blockade
was, however, associated with an increased mortality after
AAA repair.12 In a recent publication from the UK Small
Aneurysm Trial, patients taking ACE inhibitors had a faster
growth rate than those without.13
Discussion
Today, an increasing number of individuals with small
aneurysms will be identified through various screening
programmes. As high as 90% of detected AAAs are small
without indications for surgery, and the obvious and clini-
cally relevant question is if those small aneurysms can be
prevented from expansion.
Several pathophysiologically reasonable substances have
been tested in cohort as well as randomised studies.
Table 1 Cohort studies on pharmacological interventions.
Author No Substances studied Expansion rate, mm/y P-value
Biancari19 2002 41 ß-block vs control 1.5 vs 2.2 NS
Brady6 2004 1743 Antihypertensives vs no 2.6 vs 2.7 NS
Ferguson20 2010 652 Statin vs no statin OR 1.04 NS
Gadowski21 1994 121 ß-block vs control 3.0 vs 4.4 0.07
Leach22 1988 27 ß-block vs control 1.7 vs 4.4 NS
Lindholt23 2001 137 ß-block vs control 1.6 vs 2.5 0.01
Lindholt24 2008 148 ASA vs no ASA 2.5 vs 2.2 NS
Mosorin25 2008 121 Statin vs no statin 1.9 vs 2.6 NS
Schlo¨sser26 2008 230 Lipid lowering vs no Diff. 1.21 <0.02
Schouten27 2006 150 Statin vs no statin 2.0 vs 3.6 <0.001
Sukhija28 2006 130 Statin vs control 0 vs 0.4 <0.001
Sweeting13 2010 1701 ACEi vs no 3.33 vs 2.77 0.009
Thompson29 2010 1231 ACE vs no
Statin vs no
Diff 0.28
Diff 0.29
NS
NS
Walton30 1999 78 NSAID vs control 1.5 vs 3.2 <0.01
Wilminck31 2002 5811 Antihypertensives vs no 0.5 vs 0.8 NS
Pharmacological Interventions 665Unfortunately, the study methodology has been suboptimal
and, of the seven RCTs, only three had performed a pre-
study power calculation. This is necessary to decide on
a sufficient sample size. Of the substances tested so far,
statins and macrolides should be in focus for further well-
conducted trials. The seemingly positive effects of statins
in the cohort studies should be verified in RCTs.
Studying statins in RCTs may, however, be difficult in the
future as many patients already are on statin medication,
and, moreover, statin treatment may decrease the risk for
death, myocardial infarction and stroke, at least
postoperatively.14,15
Regarding NSAIDs, the results are dubious but a subgroup
analysis in one of the macrolide trials indicates an inhibi-
tory effect on AAA expansion with acetylsalicylic acid.16
Existing studies are usually of rather short duration with
insufficient follow-up time in the perspective of aneurysmal
development. An effect of ß-blockers seems to have been
excluded (three RCTs) and is, moreover, poorly tolerated by
patients.
There are a number of studies on several potential
biomarkers for aneurysm expansion,17 but using them as the
sole end point in studies on pharmacological prophylaxis of
expansion is not recommended, as their clinical relevance
is not yet known. Until more knowledge is available, theTable 2 RCTs on pharmacological interventions for attenuation
Author No Substances st
Høgh32 2009 84 roxithromycin
Karlsson16 2009 259a azithromycin
Lindholt33 1999 54 ß-block vs pl
Mosorin34 2001 32 doxycyclin vs
Propranolol35 2002 548a ß-block vs pl
Vammen36 2001 92a roxithromycin
a Statistical power calculation.biomarkers must be considered as surrogate end points and
should be in focus for research.
There are a number of difficulties in studying an effect
on expansion rate of AAA. The expansion is probably
complex, influenced by several factors (Fig. 1), which could
also vary between individuals. The mean expansion rate on
a group basis is exponential,18 meaning that there must be
a correction for initial diameter but this should be of less
importance in an RCT of sufficient size. Moreover, the
expansion rate is individually unpredictable and does not
follow a simple mathematical formula. Doses and duration
of various potential pharmacotherapies are insufficiently
known. Although risk of rupture increases with aneurysmal
size, the true relationship between size, expansion rate and
rupture is unclear, and several factors are probably of
importance. Hence, for instance, the aneurysmal volume,
the presence of ‘blebs’ and the amount of intraluminal
thrombus material have been mentioned as important for
expansion as well as rupture to occur. Expansion rate is,
however, a reasonable surrogate for risk of rupture.
In conclusion, more properly designed RCTs are needed
before we know how to pharmacologically attenuate aneu-
rysmal expansion with the ultimate aim to prevent rupture.
The increasing number of aneurysms detected by screening
should, as far as possible, be used for such studies.of AAA expansion.
udied Expansion rate mm/y p-value
vs placebo 1.6 vs 2.5 0.055
vs placebo 2.2 vs 2.2 NS
acebo 3.1 vs 2.8 NS
placebo 0 vs 2 NS
acebo 2.2 vs 2.6 NS
vs placebo 1.6 vs 2.8 0.002
Table 3 Summary of studies on pharmacological intervention for attenuation of AAA expansion.
Type of study No of patients (no of studies) No of studies with effect/without effect
Statins NSAID ACEi ß-block Macrolides Antihyper-tensives
Cohort 12,321 (15)a 3/3 1/1 e/2 1/3 e e/2
RCT 1069 (6) e e e e/2 2/2 e
a In one study29 both statin and ACEi were studied.
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